Search Result

Results for "

Anti-Leukemia

" in MedChemExpress (MCE) Product Catalog:

標的別:	Akt (1) Amino Acid Derivatives (1) Antibiotic (1) Apoptosis (19) Autophagy (4) Bacterial (2) c-Myc (1) Casein Kinase (1) Caspase (2) CDK (1) Checkpoint Kinase (Chk) (1) Deubiquitinase (2) Dihydrofolate reductase (DHFR) (1) DNA Methyltransferase (2) DNA/RNA Synthesis (5) DYRK (1) EGFR (1) Endogenous Metabolite (2) Epigenetic Reader Domain (6) ERK (1) Estrogen Receptor/ERR (1) Farnesyl Transferase (3) FLT3 (2) Hapten (1) HDAC (3) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) Isotope-Labeled Compounds (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) NF-κB (1) p38 MAPK (1) Parasite (1) Polo-like Kinase (PLK) (1) PROTACs (1) Reactive Oxygen Species (ROS) (2) Reference Standards (2) RET (1) SARS-CoV (2) STAT (1) Topoisomerase (1) VEGFR (2) Wee1 (1)
研究分野別:	Cancer (42) Cardiovascular Disease (1) Infection (6) Inflammation/Immunology (3) Neurological Disease (1)

標的別:

Akt (1)

Amino Acid Derivatives (1)

Antibiotic (1)

Apoptosis (19)

Autophagy (4)

Bacterial (2)

c-Myc (1)

Casein Kinase (1)

Caspase (2)

CDK (1)

Checkpoint Kinase (Chk) (1)

Deubiquitinase (2)

Dihydrofolate reductase (DHFR) (1)

DNA Methyltransferase (2)

DNA/RNA Synthesis (5)

DYRK (1)

EGFR (1)

Endogenous Metabolite (2)

Epigenetic Reader Domain (6)

ERK (1)

Estrogen Receptor/ERR (1)

Farnesyl Transferase (3)

FLT3 (2)

Hapten (1)

HDAC (3)

HIF/HIF Prolyl-Hydroxylase (1)

Histone Methyltransferase (1)

Isotope-Labeled Compounds (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

NF-κB (1)

p38 MAPK (1)

Parasite (1)

Polo-like Kinase (PLK) (1)

PROTACs (1)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

RET (1)

SARS-CoV (2)

STAT (1)

Topoisomerase (1)

VEGFR (2)

Wee1 (1)

研究分野別:

Cancer (42)

Cardiovascular Disease (1)

Infection (6)

Inflammation/Immunology (3)

Neurological Disease (1)

阻害剤およびアゴニスト

ペプチド

天然物

同位体標識化合物

製品番号	製品名	Target	研究分野	構造式

HY-13765

6-Thioguanine 10+ Cited Publications Thioguanine; 2-Amino-6-purinethiol	SARS-CoV Deubiquitinase DNA Methyltransferase Autophagy Apoptosis Endogenous Metabolite	Infection Inflammation/Immunology Cancer
6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC₅₀s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

HY-30272

Monobenzone 1 Publications Verification	Hapten	Cancer
Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and exhibits good potential for vitiligo research. Monobenzone is a potent inhibitor of RNR (Ribonucleotide reductase) enzyme activity by targeting RRM2 (a regulatory small subunit M2 of RNR) protein, and thus has significant anti-leukemia efficacy in vitro and in vivo. Monobenzone inhibits acute myeloid leukemia (AML) cells proliferation and DNA synthesis, induces cell cycle arrest, and Apoptosis .

HY-114162

VTP50469 10+ Cited Publications SNDX-50469	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 has potently anti-leukemia activity .

HY-16273A

L-778123 hydrochloride 5 Publications Verification	Farnesyl Transferase	Cancer
L-778123 hydrochloride is a dual inhibitor of FPTase and GGPTase-I, with IC₅₀ values of 2 nM and 98 nM respectively.

HY-16273

L-778123 5 Publications Verification	Farnesyl Transferase	Cancer
L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC₅₀s of 2 nM and 98 nM respectively .

HY-N0840

Bruceantin 2 Publications Verification (-)-BruceAntin; NCI165563; NSC165563	c-Myc Caspase Mitochondrial Metabolism Apoptosis Parasite	Infection Cancer
Bruceantin ((-)-Bruceantin) is a quassinoid found in B. javanica. Bruceantin activates caspase signaling pathway, causes the mitochondrial dysfunction, inhibits cell proliferation, induces cell differentiation and apoptosis. Bruceantin exhibits anti-leukemia and antiprotozoal activities .

HY-111380

EHT 1610 2 Publications Verification	DYRK	Neurological Disease
EHT 1610 is a potent inhibitor of DYRK, with IC₅₀s of 0.36 nM (DYRK1A), 0.59 nM (DYRK1B), respectively. EHT 1610 exhibits antileukemia effect, regulates cell cycle and induces cell apoptosis ^- .

HY-150109

Purinostat mesylate	HDAC Apoptosis	Cancer
Purinostat mesylate is a selective inhibitor of HDAC. Purinostat mesylate inhibits class I and class IIb HDACs with IC₅₀s from 0.81 to 11.5 nM. Purinostat mesylate induces apoptosis and affects cell cycle of LAMA84 and 188 BL-2 cells, and shows potently anti-leukemia effects in vivo. Purinostat mesylate can be used for the research of lymphoblastic leukemia .

HY-114162A

VTP50469 fumarate 10+ Cited Publications SNDX-50469 fumarate	Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 fumarate is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 fumarate has potently anti-leukemia activity .

HY-158341

IOX5	HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
IOX5 is a selective prolyl hydroxylase (PHD) inhibitor with an IC₅₀ of 0.19 μM for PHD2. IOX5 stabilizes HIF-1α in acute myeloid leukemia (AML) cells, inhibits cell proliferation and induces apoptosis. IOX5 has anti-leukemia activity .

HY-147868

DC-CPin711	Epigenetic Reader Domain Apoptosis	Cancer
DC-CPin711 is a potent and selective inhibitor of CREB-binding protein (CBP) bromodomain with an IC₅₀ of 0.0626 μM. DC-CPin711 arrests cell cycle at G1 phase and induces apoptosis .

HY-13765R

6-Thioguanine (Standard) Thioguanine (Standard); 2-Amino-6-purinethiol (Standard)	Reference Standards SARS-CoV Deubiquitinase DNA Methyltransferase Autophagy Apoptosis Endogenous Metabolite	Infection Inflammation/Immunology Cancer
6-Thioguanine (Standard) is the analytical standard of 6-Thioguanine. This product is intended for research and analytical applications. 6-Thioguanine (Thioguanine; 2-Amino-6-purinethiol) is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC₅₀s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

HY-168936

DP-15	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
DP-15 is the degrader for GSPT1 and BRD4 with DC₅₀s of 5.25 nM and 0.48 nM. DP-15 exhibits anti-proliferative activity of AML cells and NHL cells with an IC₅₀ of nanomolar levels, arrests the cell cycle at G1 phase, and induces apoptosis in MOLM13. DP-15 exhibits anti-leukemia activity in MOLM-13 xenograft mouse models . (Pink: ligand for target protein JQ-1 carboxylic acid (HY-78695); Black: linker (HY-W262798); Blue: ligand for E3 ligase Cereblon Thalidomide-5-OH (HY-23095))

HY-W011156

Mpa(Trt)	Amino Acid Derivatives	Others
Mpa(Trt) is a 3-mercaptopropionic acid derivative containing a trityl protecting group (Trt) and can be used to synthesize compounds with anti-leukemia activity .

HY-178155

AP232	DNA/RNA Synthesis Autophagy	Cancer
AP232 is a selective U2AF1-UHM Inhibitor with an IC₅₀ of 7.96 μM. AP232 exhibits 2.8-24-fold selectivity against other UHM-containing proteins. AP232 exerts anti-leukemia activity and shows higher activities in cell lines carrying splicing factor mutations. AP232 can induce leukemia cells G2/M and G1 arrest, impair lysosome acidification, and inhibit autophagy. AP232 can be used for the research of cancer, such as Leukemia .

HY-159646A

(R,R)-BMS-986397	Casein Kinase	Cancer
(R,R)-BMS-986397 is a CK1α degrader (DC₅₀ between 0.1-0.5 pM). (R,R)-BMS-986397 can be used in anti-leukemia research .

HY-139193

TH1760	DNA/RNA Synthesis	Cancer
TH1760 is an inhibitor of NUDIX-type 15 (NUDT15) with an IC₅₀ value of 25 nM. TH1760 sensitizes cells to 6-thioguanine by enhancing the accumulation of 6-thio- (d) GTP in nucleic acids. TH1760 enhances the anti-leukemia effect of thiopurine .

HY-114162R

VTP50469 (Standard) SNDX-50469 (Standard)	Reference Standards Epigenetic Reader Domain Apoptosis	Cancer
VTP50469 (Standard) is the analytical standard of VTP50469. This product is intended for research and analytical applications. VTP50469 is a potent, highly selective and orally active Menin-MLL interaction inhibitor with a K_i of 104 pM. VTP50469 has potently anti-leukemia activity .

HY-124069

M-525	Epigenetic Reader Domain	Cancer
M-525 is a first-in-class, highly potent, irreversible and covalent menin-MLL protein-protein interaction inhibitor. M-525 binds to menin with an IC₅₀ of 3 nM and achieves low nanomolar potencies in cell growth inhibition and in suppression of MLL regulated gene expression in MLL leukemia cells. Anti-leukemia activity .

HY-178155A

AP232 dihydrochloride	DNA/RNA Synthesis Autophagy	Cancer
AP232 dihydrochloride is a selective U2AF1-UHM Inhibitor with an IC₅₀ of 7.96 μM. AP232 dihydrochloride exhibits 2.8-24-fold selectivity against other UHM-containing proteins. AP232 dihydrochloride exerts anti-leukemia activity and shows higher activities in cell lines carrying splicing factor mutations. AP232 dihydrochloride can induce leukemia cells G2/M and G1 arrest, impair lysosome acidification, and inhibit autophagy. AP232 dihydrochloride can be used for the research of cancer, such as Leukemia .

HY-16273B

L-778123 dihydrochloride	Farnesyl Transferase	Cancer
L-778123 dihydrochloride is a dual FPTase and GGPTase-I inhibitor, with IC₅₀s of 2 nM and 98 nM, respectively .

HY-172364

PLK1-IN-12	Polo-like Kinase (PLK)	Cancer
PLK1-IN-12 is a highly selective and orally active PLK1 inhibitor with an IC₅₀ of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC₅₀: >10000 nM) and PLK3 (IC₅₀: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .

HY-W077242

1,4-Anthraquinone	DNA/RNA Synthesis	Cancer
1,4-Anthraquinone is a potent anticancer agent. 1,4-Anthraquinone blocks nucleoside transport, inhibits macromolecule synthesis, induces DNA fragmentation, and decreases the growth and viability of cancer cells. 1,4-Anthraquinone can be used to research anti-leukemia .

HY-175261

DHI1	CDK Wee1 Checkpoint Kinase (Chk)	Cancer
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC₅₀ = 21.83 μM) and HL-60 (IC₅₀ = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .

HY-122359A

rel-Levormeloxifene rel-L-Centchroman; Ormeloxifene	Estrogen Receptor/ERR Apoptosis Reactive Oxygen Species (ROS)	Cancer
rel-Levormeloxifene (rel-L-Centchroman) is the relative configuration of Levormeloxifene (HY-122359). rel-Levormeloxifene is a selective estrogen receptor modulator (SERM). rel-Levormeloxifene inhibits proliferation of leukemia cells with IC₅₀ about 7 μM, arrests cell cycle at G0/G1 phase, and induces apoptosis. rel-Levormeloxifene induces differentation of myelogenesis leukemia, and enhances ROS production in K562 cells .

HY-N1112

Uncargenin C	Others	Cancer
Uncargenin C is a triterpenoid, which can be isolated from Uncaria rhychophyllo Miq. Jacks. The intermediate of Uncargenin C has anti-leukemia activity, but not itself .

HY-170323

4-TM.P	Apoptosis	Cancer
4-TM.P binds to the minor groove of DNA, inhibits proliferation of cancer cell K562 with an IC₅₀ of 25 µM, arrests the cell cycle at G0/G1 phase, and induces apoptosis in cell K562. 4-TM.P can be used in anti-leukemia research .

HY-168860

Antituberculosis agent-13	Bacterial	Infection Cancer
Antituberculosis agent-13 (Compound 11) inhibits Mycobacterium tuberculosis, that inhibits Mtb wildtype and mutated strains with IC₅₀ of 4-62.5 nM. Antituberculosis agent-13 exhibits anti-leukemia activity that inhibits MOLM-13 with IC₅₀ of 3.8 μM .

HY-149805

Anticancer agent 110	Apoptosis	Cancer
Anticancer agent 110 is an anticancer agent with in vitro anticancer activity and excellent anti-leukemia potency. Anticancer agent 110 is highly cytotoxic to K-562 lineage chronic myelogenous leukemia cells at nanomolar concentrations. Anticancer agent 110 causes DNA damage and leads to apoptosis .

HY-N14586

Roridin J	Others	Cancer
Roridin J is a macrocyclic trichothecene and has anti-leukemia effect in mice .

HY-N14720

Demethylolivomycin A	Antibiotic Bacterial	Infection Cancer
Demethylolivomycin A is an antitumor antibiotic. Demethylolivomycin A has anti-Gram-positive bacteria and anti-leukemia P388 activity .

HY-163725

DHFR-IN-18	Dihydrofolate reductase (DHFR)	Cancer
DHFR-IN-18 (compound 19D) is a DHFR inhibitor. DHFR-IN-18 can be used in anti-leukemia research .

HY-161798

Orpinolide	Others	Cancer
Orpinolide is a withanolide analog that has anti-leukemia properties. It disrupts the internal balance of the Golgi apparatus, which is related to signaling through inositol 4-phosphate at the interface of the endoplasmic reticulum and Golgi membrane .

HY-168083

Dot1L-IN-9	Histone Methyltransferase	Cancer
Dot1L-IN-9 (Compound 12) is a DOT1L inhibitor (IC₅₀: 125 nM). Dot1L-IN-9 reduces H3K79 dimethylation. Dot1L-IN-9 can be used for anti-leukemia research .

HY-161516

HDAC6-IN-42	HDAC	Cancer
HDAC6-IN-42 (compound 2b) is an HDAC6 inhibitor (IC₅₀=0.009 μM). HDAC6-IN-42 shows significant anti-leukemia activity and synergistic effect with Decitabine (HY-A0004). HDAC6-IN-42 can be used for the AML research .

HY-149539

PLM-101	FLT3 RET	Cancer
PLM-101 is an orally available anticancer agent targeting FLT3 and RET with inhibitory activity against acute myeloid leukemia cells. PLM-101 inhibits RET, thereby inducing autophagic degradation of FLT3; and it inhibits the PI3K and Ras/ERK pathways, resulting in anti-leukemia activity. PLM-101 has anti-tumor efficacy in a mouse MV4-11 flank xenograft model (dose: 3, 10 mg/kg; po) and an allogeneic xenograft mouse model (dose: 40 mg/kg; po) .

HY-141844

HDAC/BET-IN-1	HDAC	Cancer
HDAC/BET-IN-1 displays submicromolar inhibitory activity against HDAC1 and 6 (IC₅₀ = 0.163 μM and 0.067 μM), and BRD4 (K_i = 0.076 μM), and possess potent antileukemia activity.

HY-119827

Moflomycin F 860191	Topoisomerase	Cancer
Moflomycin (F 860191) is a compound with strong anti-leukemic activity and low mutagenicity. Moflomycin has an antiproliferative effect on the leukemic cell line HL60 in vitro (IC₅₀=2.9 nM) . Moflomycin enhances topoisomerase II-induced DNA breaks and free radical production .

HY-154971

Ara-SH	Apoptosis	Cancer
Ara-SH is a Cytarabine mercaptopropionic acid-substituted derivative. Ara-SH is used as the trigger to fabricate a smart Cytarabine and Venetoclax-coloaded nanoparticle (AV-NP) through self-assembly. Ara-SH exhibits remarkable synergistic antileukemia effects in vitro and in vivo .

HY-162462

Antitumor agent-151	Apoptosis	Cancer
Antitumor agent-151 (7k) is a significant HsClpP agonist and an antileukemia drug candidate. Antitumor agent-151 (7k) exhibits remarkably enhanced proteolytic activity of HsClpP (EC₅₀ = 0.79 μM) and antitumor activity in vitro (IC₅₀ = 0.038 μM). Antitumor agent-151 (7k) induces apoptosis .

HY-168073

EGFR/VEGFR2-IN-1	EGFR VEGFR Apoptosis Microtubule/Tubulin	Cancer
EGFR/VEGFR2-IN-1 (Compound 10e) is a VEGFR-2 and EGFR inhibitor (IC₅₀: 0.26 and 0.14 μM respectively). EGFR/VEGFR2-IN-1 inhibits tubulin polymerization with an IC₅₀ of 40.9 μM. EGFR/VEGFR2-IN-1 induces apoptosis. EGFR/VEGFR2-IN-1 can be used for research of antileukemia and antilymphoma .

HY-W653745

6-Thioguanine-13C2,15N Thioguanine-¹³C₂,¹⁵N; 2-Amino-6-purinethiol-¹³C₂,¹⁵N	Isotope-Labeled Compounds	Others
6-Thioguanine-13C2,15N (Thioguanine-13C2,15N) is the ¹³C and ¹⁵N labeled 6-Thioguanine (HY-13765). 6-Thioguanine is an anti-leukemia and immunosuppressant agent, acts as an inhibitor of SARS and MERS coronavirus papain-like proteases (PLpros) and also potently inhibits USP2 activity, with IC₅₀s of 25 μM and 40 μM for Plpros and recombinant human USP2, respectively.

HY-180782

Triphenyltin(IV) diisopropyl dithiocarbamate	DNA/RNA Synthesis Reactive Oxygen Species (ROS) Caspase Apoptosis	Cancer
Triphenyltin(IV) diisopropyl dithiocarbamate (Compound OC2) is an anti-leukemia agent. Triphenyltin(IV) diisopropyl dithiocarbamate exhibits extremely strong cytotoxicity towards Jurkat cells, with an IC₅₀ value of 0.1 μM. Triphenyltin(IV) diisopropyl dithiocarbamate causes DNA damage, which subsequently leads to mitochondrial dysfunction, a large amount of ROS production, and ultimately results in the activation of the mitochondrial apoptosis pathway (involving the activation of Caspase-9/-3) and the G0/G1 phase cell cycle arrest, all of which jointly lead to the death of leukemia cells .

HY-179497

FLT3-IN-37	FLT3 VEGFR Akt STAT ERK Apoptosis	Cancer
FLT3-IN-37 (Compound 6z) is a potent inhibitor of FLT3-ITD, with IC₅₀ values of 1.5 and 3.4 nM for FLT3-ITD and TEL-VEGFR2, respectively. FLT3-IN-37 exhibits high selectivity for wild-type FLT3 (WT) and c-Kit. FLT3-IN-37 inhibits FLT3 phosphorylation and downregulates the expression of p-Akt, p-STAT5, and p-ERK. FLT3-IN-37 exerts anti-leukemia effects by blocking the cell cycle and inducing apoptosis (apoptosis). FLT3-IN-37 can be used for research on acute myeloid leukemia (AML) .

HY-N2423B

(E/Z)-Sinigrin free base (E/Z)-Allyl-glucosinolate free base; (E/Z)-2-Propenyl-glucosinolate free base	NF-κB p38 MAPK Apoptosis	Cardiovascular Disease Infection Inflammation/Immunology Cancer
(E/Z)-Sinigrin ((E/Z)-Allyl-glucosinolate; (E/Z)-2-Propenyl-glucosinolate) free base is an orally active aliphatic thioglucoside *anti-leukemia* compound. Allyl isothiocyanate, produced by the hydrolysis of (E/Z)-sinigrin free base by myrosinase, has an IC₅₀ of 2.71 μM against HL60 leukemia cells. The hydrolysis products of (E/Z)-sinigrin free base can further activate apoptosis pathways, inhibit NF-κB and MAPK signaling pathways, and induce phase II metabolic enzyme activity, thus exhibiting *anti-cancer, anti-inflammatory, antibacterial, antioxidant, and wound healing activities. (E/Z)-Sinigrin free base can be used in research on cancer, inflammation-related diseases (such as atherosclerosis), and infectious diseases. (E/Z)-Sinigrin free base can be naturally extracted from the seeds of Brassica nigra, Brassica juncea, and other Brassicaceae plants such as broccoli and Brussels sprouts. Methyl pechueloate is a guaiane-type sesquiterpene ester compound and a potential precursor of xerantholide. It is useful in the structural elucidation and biosynthetic pathway studies of sesquiterpenoids. Methyl pechueloate can be naturally extracted from the aerial parts of Pechuel-Loeschea leibnitziae* (Kuntze) O. Hoffm .

製品番号	製品名	Target	研究分野